We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+45.71%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.25B
AUM Growth
+$294M
Cap. Flow
+$131M
Cap. Flow %
10.43%
Top 10 Hldgs %
64.99%
Holding
47
New
11
Increased
13
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$54.1M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$50.3M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$44M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$37.2M
5
AKBA icon
Akebia Therapeutics
AKBA
+$36.3M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$70.4M
2
XLRN
Acceleron Pharma
XLRN
+$46M
3
ABMD
Abiomed Inc
ABMD
+$31.4M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$26.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALA
26
DELISTED
Calithera Biosciences, Inc
CALA
$11.9M 0.95%
+113,085
New +$13.4M
LQDA icon
27
Liquidia Corp
LQDA
$7.48B
$10.8M 0.86%
1,277,955
– –
ARVN icon
28
CALL
Arvinas
ARVN
$518M
$6.83M 0.55%
203,500
+100,000
+97% +$4.25M
DNLI icon
29
Denali Therapeutics
DNLI
$3.65B
$6.77M 0.54%
+280,000
New +$6.58M
VRAY
30
DELISTED
ViewRay, Inc.
VRAY
$6.21M 0.5%
2,773,811
– –
OYST
31
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$6.2M 0.5%
+214,631
New +$6.47M
XLRN
32
DELISTED
Acceleron Pharma
XLRN
$5.53M 0.44%
58,056
-477,571
-89% -$46M
KDMN
33
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.46M 0.28%
+675,679
New +$3.03M
TPST icon
34
Tempest Therapeutics
TPST
$13.7M
$2.57M 0.21%
7,491
-1,380
-16% -$551K
PBYI icon
35
Puma Biotechnology
PBYI
$404M
$965K 0.08%
+92,502
New +$957K
NGNE icon
36
Neurogene
NGNE
$656M
$233K 0.02%
703
-1,314
-65% -$343K
ARVN icon
37
Arvinas
ARVN
$518M
– –
-118,330
Closed -$5.02M
AXSM icon
38
Axsome Therapeutics
AXSM
$11.2B
– –
-100,100
Closed -$5.89M
KURA icon
39
Kura Oncology
KURA
$800M
– –
-179,700
Closed -$1.79M
TGTX icon
40
CALL
TG Therapeutics
TGTX
$7.96B
– –
-1,000,000
Closed -$9.84M
YARW
41
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
– –
-459
Closed -$4.43M
ABMD
42
DELISTED
Abiomed Inc
ABMD
– –
-216,144
Closed -$31.4M
CCXI
43
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-357,379
Closed -$14.4M
MYOK
44
CALL
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-500,000
Closed -$23.4M
MYOK
45
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-364,163
Closed -$17.1M
MNTA
46
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-979,400
Closed -$26.6M
BHVN
47
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-1,000,000
Closed -$34M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Great Point Partners held 47 positions worth $1.25B, up 31% from $957M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Great Point Partners deployed $131M of net new capital in Q2 2020, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 542,200 shares worth $34.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $70.4M trimmed.

  • Great Point Partners's largest Q2 2020 buy was Global Blood Therapeutics, Inc.: 542,200 shares worth $34.2M.
  • Great Point Partners added most to Constellation Pharmaceuticals, Inc. in Q2 2020, an estimated $54.1M increase.
  • Great Point Partners's biggest Q2 2020 reduction was PTC Therapeutics, cutting an estimated $70.4M.
  • Great Point Partners fully exited Abiomed Inc in Q2 2020, selling an estimated $31.4M.
  • Great Point Partners's ten largest holdings make up 65% of its $1.25B portfolio in Q2 2020.
  • Great Point Partners opened 11 new positions and closed 11 in Q2 2020.
  • Great Point Partners's portfolio value rose 31% quarter-over-quarter to $1.25B.

Based on Great Point Partners's 13F filing for Q2 2020, filed 14 Aug 2020.